They aren't just "pandemic stocks." ...

Pfizer has reached a turning point.

A few years ago, Pfizer (NYSE: PFE) saw revenue soar to record heights thanks to coronavirus-related sales, from its vaccine Comirnaty and its treatment Paxlovid. On top of this, the company's ...

PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.

In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig significantly improved eczema severity versus placebo in adults with ...

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

Pfizer is spinning off a big chunk of the company, culminating a rare tear of major deals aimed at reshaping the drugmaker into a slimmed-down version with faster, more-sustainable growth. The biggest ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...